Kindred Biosciences Submits KIND-012 New Animal Drug Application Technical Section for Chemistry, Manufacturing, and Controls to FDA

San Francisco, CA (December 17, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Chemistry, Manufacturing, and Controls (CMC) technical section of the New Animal Drug Application (NADA) for KIND-012. Positive topline results from the pivotal field study […]

Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-012 for Pyrexia in Horses, and Provides Other Product Updates

KIND-012 study meets primary endpoint with p<0.0001. Data to be filed with the FDA for approval. SentiKind study misses primary endpoint. Conference call and webcast scheduled for 5:00 p.m. Eastern Time today. San Francisco, CA (November 16, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, […]

Kindred Biosciences Announces Third Quarter 2015 Financial Results

San Francisco, CA (November 9, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the third quarter ended September 30, 2015 and provided updates on its programs. Development and Corporate Updates KindredBio continues to advance a diversified portfolio of molecules in a capital efficient manner. Some of the recent highlights include: SentiKind™, or […]

Kindred Biosciences Announces Second Quarter 2015 Financial Results

San Francisco, CA (August 10, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the second quarter ended June 30, 2015 and provided updates on its programs. Development and Corporate Updates KindredBio continues to advance a diversified portfolio of validated molecules in a capital efficient manner and has over 20 programs in development. […]

KindredBio Announces Appointment of Jennifer Elliott as Vice President of Legal Affairs and Intellectual Property

  San Francisco, CA (May 28, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced the appointment of Jennifer Elliott as Vice President of Legal Affairs and Intellectual Property. Dr. Elliott joins KindredBio from Genentech, where she most recently served as Associate General Counsel and Director of Patent Law. She had increasing levels of responsibility in […]